



1PW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/796,529 Confirmation No.: Unassigned
Applicants: Schinazi, et al.
Filed: March 8, 2004
TC/AU.: Unassigned
Examiner: Unassigned
Docket No.: 18085.105232 EMU 2000 CON2
Customer No.: 20786
Title: 2'-Fluoronucleosides

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmittal of Information Disclosure Statement

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of references AAC and BS are enclosed. All other listed references were cited during prosecution of the parent application filed as U.S.S.N. 10/081,128, now published as 2002-0198171, and grandparent application filed as U.S.S.N. 09/257,130, now issued as 6,348,587, therefore as permitted under 37 C.F.R. § 1.98(d) copies are not provided, however copies can be provided upon request. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the Applicants may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicants do not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits of the application, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Sherry M. Knowles, Esq.
Reg. No. 33,052


Dated June 23, 2004
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 23, 2004.

Tisha Hardwick

3462329_1.DOC



Substitute for Form 1470, 1470A, 1470B

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	4	Attorney Docket Number	18085.105232 EMU 2000 CON2
-------	---	----	---	------------------------	----------------------------

3461245 3.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	4,000,137	A	Dvonch, et al.	12-28-1976	
	AB	4,211,773	A	Lopez et al.	07-08-1980	
	AC	4,336,381	A	Nagata et al.	06-22-1982	
	AD	4,625,020	A	Brundidge et al.	11-25-1986	
	AE	4,666,892	A	Fox et al.	05-19-1987	
	AF	4,908,440	A	Sterzycki, et al.	03-13-1990	
	AG	5,034,518	A	Montgomery et al.	07-23-1991	
	AH	5,128,458	A	Montgomery et al.	07-09-1992	
	AI	5,210,085	A	Liotta, et al.	05-11-1993	
	AJ	5,246,924	A	Fox et al.	09-21-1993	
	AK	5,424,416	A	Jones et al.	06-13-1995	
	AL	5,426,183	A	Kjell et al.	06-20-1995	
	AM	5,446,029	A	Eriksson et al.	08-29-1995	
	AN	5,512,671	A	Piantodosi et al.	04-30-1996	
	AO	5,565,438	A	Chu et al.	10-15-1996	
	AP	5,567,688	A	Chu et al.	10-22-1996	
	AQ	5,587,362	A	Chu et al.	12-24-1996	
	AR	5,703,058	A	Schinazi et al.	12-30-1997	
	AS	5,808,040	A	Chu, et al.	09-15-1998	
	AT	5,817,799	A	Marquez, et al.	10-06-1998	
	AU	5,886,162	A	Kalman et al.	03-23-1999	
	AV	5,905,070	A	Schinazi et al.	05-18-1999	
	AW	6,103,707	A	Yamada, et al.	08-15-2000	
	AX	6,147,058	A	Yoshimura, et al.	11-14-2000	
	AY	6,232,300	B1	Schinazi, et al.	05-15-2001	
	AZ	6,348,587	B1	Schinazi et al.	02-19-2002	
	AAA	6,407,077	B1	Gosselin, et al.	06-18-2002	
	AAB	6,458,773	B1	Gosselin, et al.	10-01-2002	
	AAC	2002-0198171	A1	Schinazi et al.	12-26-2002	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/796,529
				Filing Date	March 8, 2004
				First Named Inventor	Schinazi, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	4	Attorney Docket Number	
18085.105232 EMU 2000 CON					

3461245 3.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
BA	EP	0,292,023	A2		Hoffman-LaRoche	05-24-1988		
BB	EP	0,316,017	A2		Sterzycki et al.	05-17-1989		
BC	EP	0,357,571	B1		Medivir Aktiebolag	04-03-1996		
BD	EP	0,382,526	A2		IAF Biochem International	08-18-1990		
BE	EP	0,409,227	A2		Akad. Wissenschaften der DDR	01-23-2991		
BF	EP	0,463,470	A2		Hoffman-LaRoche	01-02-1992		
BG	EP	0,839,813	A1		Yamasa Corp.	05-06-1998		
BH	WO	88/08001	A1		Aktiebolaget Astra	10-20-1988		
BI	WO	91/11186	A1		Emory University	08-08-1991		
BJ	WO	92/08727	A1		Consig. Naz. Ricerche	05-29-1992		
BK	WO	92/14743	A2		Emory University	09-03-1992		
BL	WO	94/14831	A1		Univ. of Alberta	07-07-1994		
BM	WO	95/20595	A1		Univ. Georgia Res. Found., Yale Univ.	08-03-1995		
BN	WO	96/22778	A1		Emory University	08-01-1996		
BO	WO	96/40164	A1		Emory Univ.; UAB R.F.; C.N.R.S.	12-19-1996		
BP	WO	97/28177	A1		Amersham International P.L.C.	08-07-1997		
BQ	WO	97/37993	A1		Yamasa Corporation	10-16-1997		
BR	WO	98/18430	A2		Univ. North Carolina Chapel Hill	05-07-1998		
BS	WO	99/43691	A1		Emory Univ.; Univ. Georgia R. F.	09-02-1999		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/796,529
				Filing Date	March 8, 2004
				First Named Inventor	Schinazi, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	4	Attorney Docket Number	18085.105232 EMU 2000 CON

3461245_3.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	BALAKRISHNA, P.S., et al., "Inhibition of Hepatitis B. Virus by a Novel L-Nucleoside, 2'-Fluoro-5-Methyl- -L- arabinofuranosyl Uracil," <i>Antimicrobial Agents and Chemotherapy</i> , 40(2):380-386 (February 1996).			
	CB	BORTHWICK, et al., "Synthesis and Enzymatic Resolution of Carbocyclic 2'-Ara-fluoro-Guanosine; A Potent New Anti-Herptic Agent," <i>J. Chem Soc., Chem. Commun.</i> , (1988).			
	CC	BOUFFARD, D.Y., et al., "Kinetic Studies of 2',2'-Difluorodeoxycytidine (Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase," <i>Biochemical Pharmacology</i> , 45(9):1857-1861 (May 5, 1993).			
	CD	CHENG, et al., "Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication," <i>Journal of Biological Chemistry</i> , Volume 267(20):13938-13942 (July 1992).			
	CE	CHU, et al., "Use of 2'-Fluoro-5-methyl- -L-arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B. Virus and Epstein-Barr Virus" <i>Antimicrobial Agents and Chemotherapy</i> , 39(4):979-981 (April 1995).			
	CF	FURMAN, et al., "The Anti-Hepatitis B. Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1[2-(Hydroxymethyl)-1, 3-oxathiolane-5-yl]-Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , 36(12):2686-2692 (December 1992).			
	CG	JEONG, L.S., et al., "Facile Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Down' Hydroxyl Groups. Retention of Configuration After Fluoride Opening of the Quaternized N ³ -MEM Anhydronucleosides," <i>Tetrahedron Letters</i> , 35(41):7573-7576 (1994).			
	CH	JEONG, L.S., et al., "Unanticipated Retention of Configuration in the DAST Fluorination of Deoxy-4'-thiopyrimidine Nucleosides with 'Up' Hydroxyl Groups," <i>Tetrahedron Letters</i> , 35(41):7569-7572 (1994).			
	CI	MACHIDA, H., et al., "Anti-herpesvirus activity profile of 4'-thioarabinofuranosyl purine and uracil nucleosides and activity of 1-beta-D-2'-fluoro-4'-thioarabinofuranosyl guanine and 2,6-diaminopurine against clinical isolates of human cytomegalovirus." <i>Antiviral Res.</i> , 39(2):129-137 (August, 1998).			
	CJ	MARQUEZ, V.E., et al., <i>Nucleosides & Nucleotides</i> , 14(3-5):555-558 (1995).			
	CK	MARTIN, et al., "Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides against Human Immunodeficiency Virus (HIV-1), <i>J. Med. Chem.</i> , 33:2137-2145 (1990).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/796,529
Filing Date	March 8, 2004
First Named Inventor	Schinazi, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned

Sheet	4	of	4	Attorney Docket Number	18085.105232 EMU 2000 CON
-------	---	----	---	------------------------	---------------------------

3461245 3.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	DA	MONTGOMERY, J.A., et al., "9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine," <i>J. Med. Chem.</i> , 29(11):2389-2392 (November 1986).	
	DB	NIIHATA, S., et al., "Synthesis of 2-Fluoro Sugar and Its Condensation Reaction with Silylated Thymine," <i>Bull. Chem. Soc. Jpn.</i> 68(5):1509-1512 (May 1995).	
	DC	OKABE, M., et al., "Synthesis of 1-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranosyl)cytosine (F-ddC). A Promising Agent for the Treatment of Acquired Immune Deficiency Syndrome," <i>J. Org. Chem.</i> 56:4392-4397 (February 1991).	
	DD	SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl]-1, 3-Oxathiolane-5-yl]Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , 36(11): 2423-2431 (November 1992).	
	DE	SCHINAZI, et al., Mutations in retroviral genes associated with drug resistance, <i>International Antiviral News</i> (1997).	
	DF	SIDDQUI, M.A., et al., "A New Synthetic Approach to the Clinically Useful, Anti-HIV Active Nucleoside, 9-(2,3-Dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)adenine (beta-FddA). Introduction of a 2'-beta-Fluoro Substituent via Inversion of a Readily Obtainable 2'-alpha-Fluoro Isomer," <i>Tetrahedron Letters</i> , 39(13):1657-1660 (March 26, 1998).	
	DG	STERZYCKI, et al., "Synthesis and Anti-HIV Activity of Several 2'-Fluoro-Containing Pyrimidine Nucleosides," <i>J. Med. Chem.</i> , 33(8):2150-2157 (August 1990).	
	DH	SU, T.S., et al., "Sythesis and Antiviral Effects of Several 1-(2-Deoxy-2-fluoro-B-D-arabinofuranosyl)-5-alkyluracils. Some Structure-Activity Relationships," <i>J. Med. Chem.</i> , 29:151-154 (1986).	
	DI	TOYOTA, A., et al., <i>Tetrahedron</i> , 51(32):8783-8798 (1995).	
	DJ	Van AERSCHOT, A., et al., "3'-Fluoro-2',3'-dideoxy-5-chlorouridine: Most Selective Anti-HIV-1 Agent among a Series of New 2'- and 3'-Fluorinated 2',3'-Dideoxynucleoside Analogues.", <i>J. Med. Chem.</i> 32(8):1743-1749 (August 1989).	
	DK	WANTANABE, et al., "Synthesis and Anti-HIV Activity of 2'-"Up"-Fluoro Analogues of Active Anti-Aids Nucleosides 3'-Azido-3'deoxythymidine (AZT) and 2', 3'-dideoxycytidinee (DDC)," <i>J. Med. Chem.</i> , 33:2145-2150 (1990).	
	DL	YOAHIMURA, Y., et al., <i>J. Org. Chem.</i> , 64:7912-7920 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.